Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 17,000 full-time employees. The company went IPO on 2001-07-25. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. The company also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
¿Cuál es el ratio P/E de Zimmer Biomet Holdings, Inc (ZBH)?
El ratio P/E de Zimmer Biomet Holdings, Inc es 24.9784
¿Quién es el CEO de Zimmer Biomet Holdings, Inc?
Mr. Ivan Tornos es el Chairman of the Board de Zimmer Biomet Holdings, Inc, se unió a la empresa desde 2018.
¿Qué tal es el rendimiento del precio de la acción ZBH?
El precio actual de ZBH es de $82.83, ha disminuido un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Zimmer Biomet Holdings, Inc?
Zimmer Biomet Holdings, Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Zimmer Biomet Holdings, Inc?
La capitalización bursátil actual de Zimmer Biomet Holdings, Inc es $16.0B
¿Es Zimmer Biomet Holdings, Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 28 analistas han realizado calificaciones de análisis para Zimmer Biomet Holdings, Inc, incluyendo 4 fuerte compra, 7 compra, 20 mantener, 2 venta, y 4 fuerte venta